Genprex Inc (NASDAQ:GNPX) hit a new 52-week low during trading on Thursday . The stock traded as low as $1.50 and last traded at $1.54, with a volume of 150 shares trading hands. The stock had previously closed at $1.55.
Separately, Maxim Group initiated coverage on shares of Genprex in a research report on Friday, September 14th. They issued a “buy” rating and a $5.00 price target for the company.
About Genprex (NASDAQ:GNPX)
Genprex, Inc, a clinical stage gene therapy company, develops drugs to treat cancer. Its lead product candidate is Oncoprex, an active anti-cancer agent that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). It also conducts preclinical research for developing Oncoprex to be administered with immunotherapies in NSCLC; and research into other tumor suppressor genes associated with chromosome.
Featured Article: Closed-End Mutual Funds (CEFs)
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.